As of the end of 2023, the share of HIV-positive tuberculosis patients on antiretroviral therapy (ART) in Brazil stood at an estimated 56%. Forecast data for 2024 to 2028 shows a steady annual increase of 1 percentage point, reaching 61% by 2028. On a year-on-year basis, the increase from 2024 to 2028 remains consistent at roughly 1.75% annually. A five-year compound annual growth rate (CAGR) projects an average annual growth of nearly 1.75% over this period.
Future trends to watch for include improvements in comprehensive healthcare strategies and potential new policies enhancing ART delivery to tuberculosis patients, which could accelerate this growth. Increasing coordination between tuberculosis and HIV programs will play a critical role.
